Immix Biopharma Inc reports results for the quarter ended in June - Earnings Summary

Reuters08-14

* Immix Biopharma Inc reported a quarterly adjusted loss of 15 cents per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of -24 cents. The lone analyst forecast for the quarter was for a loss of 21 cents per share.

* Reported revenue was zero; analysts expected zero.

* Immix Biopharma Inc's reported EPS for the quarter was a loss of 15 cents.

* The company reported a quarterly loss of $4.39 million.

* Immix Biopharma Inc shares had fallen by 6.6% this quarter and lost 73.3% so far this year.

FORECAST CHANGES

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Immix Biopharma Inc is $7.00 This summary was machine generated from LSEG data August 13 at 07:18 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Jun. 30 2024 -0.21 -0.15 Beat

Dec. 31 2023 -0.23 -0.23 Met

Sep. 30 2023 -0.23 -0.23 Met

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2459136285?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-08-14 03:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2459136285","market":"us","top_or_hot":-1,"title":"Immix Biopharma Inc reports results for the quarter ended in June - Earnings Summary","media":"Reuters","content":"<html><body><p>* Immix Biopharma Inc    reported a quarterly adjusted loss of 15 cents per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of -24 cents.  The lone analyst forecast for the quarter was for a loss of 21 cents per share. </p><p>   * Reported revenue was zero; analysts expected zero. </p><p>   * Immix Biopharma Inc's reported EPS for the quarter was a loss of 15 cents.</p><p>   * The company reported a quarterly loss of $4.39 million.</p><p>   * Immix Biopharma Inc shares had fallen by 6.6% this quarter and lost 73.3% so far this year.</p><p>FORECAST CHANGES</p><p>   * In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.</p><p>RECOMMENDATIONS</p><p>   * The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\" </p><p>   * The average consensus recommendation for the pharmaceuticals peer group is also \"buy\"</p><p>Wall Street's median 12-month price target for Immix Biopharma Inc is $7.00  This summary was machine generated from LSEG data August 13 at 07:18 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,</p><p>                                                MISSED</p><p>Jun. 30 2024      -0.21          -0.15          Beat</p><p>Dec. 31 2023      -0.23          -0.23          Met</p><p>Sep. 30 2023      -0.23          -0.23          Met</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immix Biopharma Inc reports results for the quarter ended in June - Earnings Summary</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmix Biopharma Inc reports results for the quarter ended in June - Earnings Summary\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-14 03:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>* Immix Biopharma Inc    reported a quarterly adjusted loss of 15 cents per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of -24 cents.  ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMMX","symbol_name":"Immix Biopharma, Inc","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2459136285","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2459136285","pubTimestamp":1723576686,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"* Immix Biopharma Inc    reported a quarterly adjusted loss of 15 cents per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of -24 cents.  Th","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"IMMX":"Immix Biopharma, Inc"},"translate_title":"Immix Biopharma Inc报告截至6月的季度业绩-收益摘要","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMMX":0.9},"content_text":"* Immix Biopharma Inc    reported a quarterly adjusted loss of 15 cents per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of -24 cents.  The lone analyst forecast for the quarter was for a loss of 21 cents per share.    * Reported revenue was zero; analysts expected zero.    * Immix Biopharma Inc's reported EPS for the quarter was a loss of 15 cents.   * The company reported a quarterly loss of $4.39 million.   * Immix Biopharma Inc shares had fallen by 6.6% this quarter and lost 73.3% so far this year.FORECAST CHANGES   * In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.RECOMMENDATIONS   * The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"    * The average consensus recommendation for the pharmaceuticals peer group is also \"buy\"Wall Street's median 12-month price target for Immix Biopharma Inc is $7.00  This summary was machine generated from LSEG data August 13 at 07:18 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,                                                MISSEDJun. 30 2024      -0.21          -0.15          BeatDec. 31 2023      -0.23          -0.23          MetSep. 30 2023      -0.23          -0.23          Met","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2459136285"}